Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT: Baricitinib for Intracerebral Hemorrhage
NCT06737705Phase 2Completed
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib in intracerebral hemorrhage (ICH) (2 arms). Primary endpoint: Favorable neurological outcome defined by modified Rankin Scale score of 0-2 at 90 days. Started Jan 2025; status: completed.
02
Drugs
baricitinib
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT06737705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737705.